Enliven Therapeutics (NASDAQ:ELVN) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Enliven Therapeutics (NASDAQ:ELVN) issued its quarterly earnings data on Wednesday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10), FiscalAI reports.

Enliven Therapeutics Price Performance

NASDAQ ELVN traded down $1.41 on Wednesday, reaching $59.70. 1,724,207 shares of the company’s stock traded hands, compared to its average volume of 1,287,011. Enliven Therapeutics has a 12 month low of $14.78 and a 12 month high of $62.32. The stock has a market cap of $3.64 billion, a PE ratio of -35.75 and a beta of 0.27. The stock has a 50-day simple moving average of $47.45 and a 200 day simple moving average of $39.05.

Insider Transactions at Enliven Therapeutics

In other news, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $50.49, for a total value of $504,900.00. Following the transaction, the director owned 41,884 shares in the company, valued at approximately $2,114,723.16. The trade was a 19.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, July 17th. The stock was sold at an average price of $52.64, for a total value of $316,787.52. Following the completion of the transaction, the chief financial officer directly owned 46,054 shares in the company, valued at $2,424,282.56. This trade represents a 11.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 32,036 shares of company stock worth $1,430,676 over the last ninety days. Insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Invesco Ltd. grew its stake in shares of Enliven Therapeutics by 4.3% in the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock worth $440,000 after purchasing an additional 913 shares during the last quarter. BNP Paribas Financial Markets raised its position in Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the last quarter. Swiss National Bank raised its position in Enliven Therapeutics by 1.7% during the 4th quarter. Swiss National Bank now owns 64,273 shares of the company’s stock valued at $990,000 after purchasing an additional 1,100 shares during the last quarter. Quantbot Technologies LP lifted its holdings in Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares during the period. Finally, Legal & General Group Plc lifted its holdings in Enliven Therapeutics by 4.8% in the 3rd quarter. Legal & General Group Plc now owns 33,765 shares of the company’s stock worth $691,000 after buying an additional 1,540 shares during the period. 95.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. HC Wainwright increased their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. JonesTrading boosted their price target on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Stifel Nicolaus increased their target price on shares of Enliven Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Finally, Mizuho upped their target price on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $70.50.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.